Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Roden

Showing results (521-530 of 1,011) with videos related to

Pageof 102
Sort By:
Clinical Pharmacology and Therapeutics|May 1, 1989
Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testingK T Murray, J T Barbey, H A Kopelman, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 24, 2019
Evaluation of lipoprotein-associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetesJ Seyfarth, D Herebian, C Reinauer, et al.
British Journal of Pharmacology|December 1, 1999
Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolismC Fürnsinn, B Brunmair, M Meyer, et al.
Cardiovascular Research|September 19, 2002
Cardiac-enriched LIM domain protein fhl2 is required to generate I(Ks) in a heterologous systemSabina Kupershmidt, Iris C-H Yang, Margaret Sutherland, et al.
The American Journal of Cardiology|September 1, 1980
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamideD M Roden, S B Reele, S B Higgins, et al.
Lancet (London, England)|August 10, 2019
PharmacogenomicsDan M Roden, Howard L McLeod, Mary V Relling, et al.
Clinical Pharmacology and Therapeutics|January 30, 2018
Benefit of Preemptive Pharmacogenetic Information on Clinical OutcomeDan M Roden, Sara L Van Driest, Jonathan D Mosley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 1998
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapyM P Bettinotti, C J Kim, K H Lee, et al.
Clinical Pharmacology and Therapeutics|May 1, 1988
The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmiasT Wang, L A Siddoway, K A Thompson, et al.
Nature|January 25, 2002
A calcium sensor in the sodium channel modulates cardiac excitabilityHanno L Tan, Sabina Kupershmidt, Rong Zhang, et al.
Pageof 102

Showing results (521-530 of 1,011) with videos related to

Sort By:
Pageof 102
Clinical Pharmacology and Therapeutics|May 1, 1989
Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testingK T Murray, J T Barbey, H A Kopelman, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 24, 2019
Evaluation of lipoprotein-associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetesJ Seyfarth, D Herebian, C Reinauer, et al.
British Journal of Pharmacology|December 1, 1999
Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolismC Fürnsinn, B Brunmair, M Meyer, et al.
Cardiovascular Research|September 19, 2002
Cardiac-enriched LIM domain protein fhl2 is required to generate I(Ks) in a heterologous systemSabina Kupershmidt, Iris C-H Yang, Margaret Sutherland, et al.
The American Journal of Cardiology|September 1, 1980
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamideD M Roden, S B Reele, S B Higgins, et al.
Lancet (London, England)|August 10, 2019
PharmacogenomicsDan M Roden, Howard L McLeod, Mary V Relling, et al.
Clinical Pharmacology and Therapeutics|January 30, 2018
Benefit of Preemptive Pharmacogenetic Information on Clinical OutcomeDan M Roden, Sara L Van Driest, Jonathan D Mosley, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 1998
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapyM P Bettinotti, C J Kim, K H Lee, et al.
Clinical Pharmacology and Therapeutics|May 1, 1988
The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmiasT Wang, L A Siddoway, K A Thompson, et al.
Nature|January 25, 2002
A calcium sensor in the sodium channel modulates cardiac excitabilityHanno L Tan, Sabina Kupershmidt, Rong Zhang, et al.
Pageof 102